A dual therapy stent that accelerates endothelial coverage and controls neo-intimal proliferation received CE mark in Europe for the treatment of coronary artery disease.

OrbusNeich’s COMBO Dual Therapy Stent uses a combination of a pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves dissipation by 90 days, according to the company. The approach is said to offer the benefits of both drug eluting stents and accelerated stent endothelialization and healing.

Hong Kong-based OrbusNeich will begin a sales roll-out in Europe and selected markets in the Asia Pacific and Middle East regions.